諾誠健華-B(09969.HK)擬向高瓴等配售2.1億股 總籌30.4億港元
格隆匯 2 月 3日丨諾誠健華-B(09969.HK)發佈公吿,2021年2月2日,公司與投資者訂立兩份認購協議,據此,公司已有條件同意配發及發行且投資者已有條件同意按個別但非共同基準認購合共210,508,000股新股份,認購價為每股認購股份14.45港元。
投資者包括投資者一(即Gaoling與YHG)及投資者二(即Vivo Opportunity Fund, L.P.)。Gaoling及YHG是根據開曼羣島法律成立的有限合夥企業。Hillhouse Capital擔任Gaoling的獨家投資經理人及YHG的一般合夥人。 投資者二為Vivo Capital LLC的受控法團的一,及Vivo Capital LLC(透過其於受控法團的權益)被視作於公司104,133,118股股份中擁有權益,約佔公司已發行股份總額的8.08%。
新股份相當於公司現有已發行股份總額的約16.33%,及經配發及發行認購股份而擴大的公司已發行股份總額的約14.04%(假設完成前並無發行其他股份)。認購價每股14.45港元較2月2日(即認購協議簽訂的日)收市價15.72港元折讓約8.08%。
估計發行認購股份的所得款項總額及所得款項淨額分別約為30.4184億港元及30.4144億港元。公司擬將所得款項淨額用於在國內和國際地區擴大和加速正在進行和計劃進行的臨牀試驗;留聘國內外人才,以增強集團在發現、臨牀、業務開發和商業化領域的能力;擴大商業團隊,以確保奧布替尼及其後續產品的成功上市;擴大和加速內部發現階段項目,包括集團在研產品中的多個IND準備階段候選藥物;為任何潛在的外部協作和授權引進機會儲備資金;及用作營運資金和其他一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.